The company's exceptional free cash flow conversion and historical earnings beat record are offset by a confirmed price downtrend — the stock is below a falling 200-day moving average — and an earnings report due today that introduces immediate binary risk into any position.
Thesis pillars
- Confirmed Technical Downtrend→Stable
- Recent Earnings Miss After Beat Streak↓Deteriorating
- Exceptional Free Cash Flow Conversion↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
ICON plc (ICLR) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $203.77: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs... Read more
Sell if holding. Engine safety override at $203.77: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 105d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
No fresh coverage since Jun 24, 2026
Recent Developments — ICON plc
Latest news
- NEWS ICON plc Stock 12‑Month Price Target Raised to $161.33, Implies 13% Upside - TradingView — TradingView Jun 24, 2026 positive
- NEWS ICLR Stock Pops As ICON plc Beats Earnings And Doubles Down On AI - StocksToTrade — StocksToTrade Jun 24, 2026 positive
- NEWS ICON plc (ICLR) Reports Strong Q1 2026 Performance with $3.3B in Gross Bookings - GuruFocus — GuruFocus Jun 24, 2026 positive
- NEWS ICLR Stock Jumps As AI Deal And Earnings Beat Support Outlook - timothysykes.com — timothysykes.com Jun 24, 2026 positive
- NEWS ICLR Stock Pops As ICON plc Bets Big On AI With Microsoft - StocksToTrade — StocksToTrade Jun 24, 2026 positive
Latest item Jun 24, 2026 · Generated 2026-11-04T12:10:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -2.9% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $203.77: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $189.51. Score 4.5/10, moderate confidence.
Analyst target: $208.16 (+2.2% upside). Prior stop was $189.51. Stop-loss: $189.51.
Target reached (2.2% upside); Quality below floor (3.7 < 4.0).
ICON plc trades at a P/E of 81.5 (forward 17.6). TrendMatrix value score: 5.7/10. Verdict: Sell.
24 analysts rate ICLR, with a consensus score of 3.8/5. 17 analysts publish price targets averaging $231.
What does ICON plc do?ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization...
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.